Better Therapeutics to Participate in Two Upcoming Investor Events

Rhea-AI Summary

Better Therapeutics (NASDAQ: BTTX) announced CEO Kevin Appelbaum will participate in two investor events. The first is a virtual fireside chat on January 26, from 12-1 p.m. EST, discussing treatments for cardiometabolic diseases and the company's lead candidate, BT-001. The second event is the Cowen 42nd Annual Health Care Conference in Boston, MA, on March 7-9, with a chat scheduled on March 7, from 2:10-2:40 p.m. EST. Replays of both sessions will be available on the Better Therapeutics investor site for 90 days.

SAN FRANCISCO--(BUSINESS WIRE)--

Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows:

• A virtual fireside chat hosted by LifeSci Capital on January 26 from 12 – 1 p.m. EST. The management team will discuss the current treatment paradigm for cardiometabolic diseases, Better Therapeutics’ approach for treating behavioral root causes using prescription digital therapeutics (PDT), and its lead candidate BT-001, a PDT for treating uncontrolled type 2 diabetes in adults, currently undergoing a potentially pivotal trial. To register for the call, please email Robert Fromberg (rfromberg@lifescicapital.com).
• The Cowen 42^nd Annual Health Care Conference taking place March 7 – 9 in Boston, MA, including a fireside chat on Monday, March 7^th, from 2:10-2:40 pm EST.
• A replay of both firesides will be available on the Presentations and Events section on the Better Therapeutics investor site (www.investors.bettertx.com) for approximately 90 days after the event.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information visit: bettertx.com

BTTX-PR

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005817/en/

Investor Relations:

Mark Heinen

IR@bettertx.com

Media:

Cassidy McClain

Cassidy.McClain@canalecomm.com

619.849.6009

Source: Better Therapeutics, Inc.

FAQ

What are the upcoming investor events for Better Therapeutics (BTTX)?

Better Therapeutics' CEO Kevin Appelbaum will participate in a virtual fireside chat on January 26 and the Cowen 42nd Annual Health Care Conference from March 7-9.

What will be discussed in Better Therapeutics' virtual fireside chat?

The virtual fireside chat on January 26 will cover treatments for cardiometabolic diseases and Better Therapeutics' lead candidate, BT-001.

When is the Cowen 42nd Annual Health Care Conference featuring Better Therapeutics (BTTX)?

The Cowen 42nd Annual Health Care Conference will take place from March 7 to March 9, with Better Therapeutics' chat on March 7, from 2:10-2:40 p.m. EST.

Where can I find replays of Better Therapeutics' investor events?

Replays of both investor events will be available on Better Therapeutics' investor site for approximately 90 days after the events.

What is BT-001 from Better Therapeutics (BTTX)?

BT-001 is Better Therapeutics' lead prescription digital therapeutic for treating uncontrolled type 2 diabetes, currently undergoing a potentially pivotal trial.